Summary
An analysis of 173 cases of non-Hodgkin's lymphoma (NHL) admitted to our hospital from January 1973 to January 1983 is presented. Of the 173 cases, 124 patients suffered from NHL of high grade malignancy according to the Kiel classification (37 centroblastic lymphoma (CB), 30 immunoblastic lymphoma (IB), 43 lymphoblastic lymphoma (LB), 14 NHL high grade malignancy unclassifiable). In addition, 26 patients with secondary high grade malignant NHL were included in the analysis (14 secondary CB, 10 secondary IB, 2 secondary LB). Also investigated were 23 patients with anaplastic centrocytic lymphoma (CC) (20 primary CC, 3 secondary CC), an entity originally classified as low grade malignant lymphoma, but showing a poor outcome and need for aggressive therapy. Symptoms at presentation of all patients are described. Of the 173 patients, 71% had an advanced stage of the disease at the time of diagnosis (Ann Arbor stage III or IV). B-symptoms were observed in 81%. Extranodal involvement, (exceptive bone marrow involvement), determined by clinical examination was seen in 55%. Survival of patients changed significantly after replacing initial radiotherapy with aggressive chemotherapy (P<0.001). Improvement of survival statistics was due to the better outcome of patients with localized stages (Ann Arbor stages I and II) as compared to those with generalized disease (P<0.002). Prognostic factors influencing survival were elevation of lactic dehydrogenase (P<0.0001) and response to therapy (P<0.0001). Histological subtypes according to the Kiel classification also showed prognostic relevance. The outcome of patients was significantly influenced by the therapeutic modalities administered.
Similar content being viewed by others
Abbreviations
- CB:
-
Centroblastic lymphoma
- CB/CC:
-
Centroblastic/centrocytic lymphoma
- CC:
-
Centrocytic lymphoma large cell (Synonyma: anaplastic centrocytic lymphoma)
- CHOP:
-
Cyclophosphamid, Adriamycin, Oncovin, Prednison
- C-MOPP:
-
Cyclophosphamid, Oncovin, Prednison, Procarbazine
- COP:
-
Cyclophosphamid, Oncovin, Prednison
- CR:
-
Complete remission
- CS:
-
Clinical stage
- IB:
-
Immunoblastic lymphoma
- LB:
-
Lymphoblastic lymphoma
References
Anderson T, De Vita VT, Simon RM, Berard CW, Canellos GP, Garvin AJ, Young RC (1982) Malignant Lymphoma: II Prognostic Factors and Response to Treatment of 473 patients of the National Cancer Institute. Cancer 50:2708–2721
Armitage JO, Dick FR, Corder MP (1981) Diffuse histiocytic lymphoma after histologic conversion: A poor prognostic variant. Cancer Treat Rep 65:413–418
Bloomfield CD, Goldman A, Dick F, Brunning RD, Kennedy BJ (1974) Multivariant analysis of prognostic factors in the non-Hodgkin's Lymphomas. Cancer 33:870–879
Baumgartner G, Heinz R, Scharl M (E1983) New chemotherapeutic schedules in bad risk NHL. Proceedings of 13th Intern Congr of Chemotherapy, part 239:5–8
Bremer K, Meusers P, Brittinger G (1980) Chemotherapie der Non-Hodgkin Lymphome. Internist 21:512–528
Brittinger G, Bartels H, Bremer K, Burger A, Dühmke E, Gunzer U, König E, Stacher A, Stein H, Theml H, Waldner R (Kieler Lymphomgruppe) (1977) Retrospektive Untersuchungen zur klinischen Bedeutung der Kiel-Klassifikation der malignen Non-Hodgkin-Lymphome. Strahlentherapie 153:228
Brittinger G, Bartels H, Common H, Dühmke E, Fülle HH, Gunzer U, Gyenes T, Heinz R, König E, Meusers P, Paukstat M, Pralle H, Theml H, Köpcke W, Thieme C, Zwingers T, Musshoff K, Stacher A, Brücher H, Herrmann F, Ludwig WD, Pribilla W, Burger-Schüler A, Löhr GW, Gremmel H, Oertel J, Gerhartz H, Koeppen KM, Boll I, Huhn D, Binder T, Schoengen A, Nowicki L, Pees HW, Scheurlen PG, Leopold H, Wannenmacher M, Schmidt M, Löffler H, Michlmayer G, Thiel E, Zettel R, Rühl U, Wilke HJ, Schwarze EW, Feller AC, Stein H, Lennert KJ (Kiel Lymphoma Study Group) (1984) Clinical and prognostic relevance of the Kiel Classification of Non-Hodgkin-Lymphomas: Results of a prospective multicenter Study by the Kiel Lymphoma Study Group. Hematological Oncology, Vol. 2, pp 269–306
Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin's diseases staging classification. Cancer Res 31:1060–1061
Ciampi A, Bush RS, Gospodarowicz M, Till JE (1981) An approach to classifying prognostic factors related to survival. Experience for non-Hodgkin's Lymphoma patients. Cancer 47:621–627
Cohen LF, Balow JE, Magrath LT, Poplack DG, Ziegler JL (1980) Acute tumor lysis syndrome. A Review of 37 patients with Burkitt's Lymphoma. Am J Med 68/4:486–491
Delbrück H, Weichert HC, Schmitt G, Firusion N, Wetter O (1978) Der Zusammenhang zwischen Prognose und Kieler-Klassifikation der malignen Non-Hodgkin Lymphome. Klin Wochenschr 56:539–543
De Vita VT, Hubbard SM (1982) The curative potential of chemotherapy in the treatment of Hodgkin's disease and Non-Hodgkin's Lymphomas. pp 280–419 in: Malignant Lymphoma (Ed.: SA Rosenberg, H.S. Kaplan) Academic Press
Dixon WD, Braun MB (1981) A Biomedical computer programs BMDP-77 Univ. of California Press — Berkeley Los Angeles London
Ferraris AM, Guitini P, Gaetini GF (1979) Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin-lymphomas. Blood 54:928–932
Fisher RI, Hubbard SM, De Vita VT, Berard CW, Wesly R, Cossman J, Young RC (1981) Factors predicting long-term survival in diffuse mixed histiocytic or undifferentiated lymphoma. Blood 58:45–51
Fisher RI, De Vita VT, Hubbard SM, Longo DL, Westly R, Chabner BA, Young RC (1983) Diffuse aggressive lymphoma: Increased survival after alternating flexible sequences of PROMACE and MOPP chemotherapy. Ann Int Med 98:304–309
Fleming ID, Mitchell St, Dilawari RA (1982) The Role of Surgery in the Management of Gastric Lymphoma. Cancer 49:1135–1141
Fram RJ, Skarin AT, Rosenthal DS, Pinkus G, Nadler LM (1983) Clinical, pathologic and immunological features of patients with non-Hodgkin's Lymphoma in a leukemic phase. Cancer 52:1220–1228
Freeman C, Berg JW, Cutler SJ (1972) Occurrence and prognosis of Extranodal Lymphomas. Cancer 29:252–260
Gerard-Marchant R, Hamlin I, Lennert K, Rilke F, Stanfeld AG, von Unnik JAM (1974) Classification of non-Hodgkin's Lymphomas. Lancet II:406–408
Glick JH, McFadden E, Costello W, Ezdinli E, Berard C, Bennett JM (1982) Nodular histiocytic lymphoma: Factors influencing prognosis and implications for aggressive treatment. Cancer 49:840–845
Hagberg H, Siegbahn A (1983) Prognostic Value of Serum Lactic Dehydrogenase in Non-Hodgkin's Lymphoma. Scand J Haematol 31:49–56
Hajnos G, Pirovino M, Rüthner JR (1976) Extranoduläre Manifestationen generalisierter maligner Lymphome. Schweiz med Wochenschr 106:234–239
Heinz R, Neumann E, Pont J, Schüller J, Walcher G, Hanak H, Radaszkiewicz T, Sinn E, Wirth M, Dittrich C, Schwarzmeier J, Kühböck J, Honetz N, Alth G, Stacher A (1983) Therapiestudie bei hochmalignen Non-Hodgkin Lymphomen (NHL). Verhandlungen der Dtsch Ges Inn Med 89:1010–1012
Horwich A, Peckham M (1983) “Bad Risk” Non Hodgkin Lymphomas. Semin Hematol 20:35–56
Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observation. J An Statis Assn 53:457–481
König E, Bartels H, Bremer K, Burger-Schüler A, Common H, Dühmke E, Engelhardt M, Fülle HH, Gunzer U, Köppen KM, Leopold H, Nowicki L, Oertel J, Petzmann S, Rühl U, Schmidt M, Schögen A, Scholle H, Stacher A, Wolf-Hornung B, Schwarze EW, Brittinger G (Kiel Lymphoma Study Group) (1981) Germinal Center Cell Lymphomas: Prognostic significance of their histologic differentiation. Blut 43:193–200
Lennert K, Mohri N, Stein H, Kaiserling E, Müller-Hermelink H (1978) Malignant Lymphomas other than Hodgkin's Disease. Handbuch d. speziellen pathologischen Anatomie und Histologie I/3b, Springer, Berlin Heidelberg New York
Mackintosh FR, Golby ThV, Podolsky WJ, Burke JS, Hoppe RT, Rosenfelt FP, Rosenberg SA, Kaplan HS (1982) Central nervous system involvement in non-Hodgkin's Lymphoma: An analysis of 105 cases. Cancer 49:586–595
Meugé C, Hoerni B, De Mascarel A, Durand B, Richaud P, Hoerni-Simon G, Chauvergne J, Lagarde C (1973) Non-Hodgkin malignant lymphomas. Clinicopathologic correlations with the Kiel classification. Retrospective analysis of a series of 274 cases. Eur J Cancer Clin Oncol 14:587–592
Miller TP, Jones SE (1979) Chemotherapy of localized histiocytic lymphoma. Lancet I:358–360
Ostrow St, Diggs CH, Sutherland J, Wiernik PH (1981) Causes of death in patients with non-Hodgkin's lymphoma. Cancer 48:779–782
Ree HJ, Reege VP, Knisley RE, Thayer WR, D'Amico RP, Song JY, Crowley JP (1980) Malignant lymphoma of Waldeyer's ring following gastrointestinal lymphoma. Cancer 46:1528–1535
Riehm H, Gardner H, Welte K (1977) Die Westberliner Studie zur Behandlung der akuten lymphoblastischen Leukämie des Kindes — Erfahrungsbericht nach 6 Jahren. Klin Pediatr 189:89–95
Rosenberg SA (1982) The non-Hodgkin's lymphoma pathologic classification project: national cancer institute sponsered study of classifications of non-Hodgkin's lymphomas. Summary and Description of a Working Formulation for Clinical Usage. Cancer 49:2112–2135
Rudders RA, Ross ME, Delellis RA (1980) Primary extranodal lymphoma: response to treatment and factors influencing prognosis. Cancer 42:406–416
Schneider RJ, Seibert K, Passe S, Little C, Gee T, Lee BJ, Mike V, Young CW (1980) Prognostic Significance of Serum Lactate Dehydrogenase in Malignant Lymphome. Cancer 46:139–143
Shimm DS, Dosoretz DE, Anderson Th, Linggood RM, Harris NL, Wang CC (1983) Primary gastric lymphoma: an analysis with emphasis of prognostic factors and radiation therapy. Cancer 52:2044–2048
Weingrad DN, Decosse JJ, Sherlock P, Straus D, Lieberman PhH, Filippa DA (1982) Primary gastrointestinal lymphoma: A 30-year review. Cancer 49:1258–1265
Young RC, Howser DM, Anderson T, Fisher RI, Jaffe E, De Vita VT (1979) Central nervous system complications of non-Hodgkin's lymphoma: The potential role for prophylatic therapy. Am J Med 66:435–443
Ziegler JL (1977) Treatment results of 54 American patients with Burkitt's lymphoma are similar to the African experience. N Engl J Med 297:75–80
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Heinz, R., Hanak, H. & Stacher, A. Progress in the management of high risk non-Hodgkin's lymphomas. Klin Wochenschr 63, 619–626 (1985). https://doi.org/10.1007/BF01732856
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01732856